KALA BIO, Inc. (KALA) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$0.55

From 52W high−99.95%

Volume79870.00

Market cap$10.42M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

$0.55

From 52W high

−99.95%

Volume

79870.00

Market cap

$10.42M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.4x

P/E (TTM)

—

RSI (14)

35.9

MomentumView details →

1D Return

−4.53%

YTD Return

−98.03%

SummaryUpdated Jun 1, 2026

Kala Pharmaceuticals, Inc. (NASDAQ:KALA) is a biopharmaceutical company founded in 2009 and headquartered in Watertown, Massachusetts. The company was originally incorporated as Hanes Newco, Inc. before changing its name in December 2009 and went public in July 2017. Kala has undergone significant strategic transformation in recent years, transitioning from a commercial-stage company with marketed eye care products to a research-focused organization developing novel therapies for ocular diseases using proprietary drug delivery technologies.

Ask drillr about KALA BIO, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.4x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

1.2x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−111.46%

ROA (TTM)

−95.26%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+9.67%

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

+67.39%

EBITDA YoY

+74.58%

MomentumView details →

1D Return

−4.53%

YTD Return

−98.03%

1Y Return

−99.94%

RSI (14)

35.9

vs 50D SMA

−25.97%

vs 200D SMA

−95.40%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

6.88x

Quick Ratio

6.88x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$21.32

EPS Surprise

−255.33%

Beats (12Q)

6/12

Next Q EPS Est

−$6.00

Avg Surprise (4Q)

−39.22%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−10.08M

Op. CF (TTM)

−19.86M

Next earningsNov 10, 2026 →

Latest newsMore news →

KALA BIO added Yenvy Truong, founder of The LSM Group, to its advisory team.3d ago

KALA BIO, Inc. signed an exclusive distribution and reseller agreement with Virotek Inc. to distribute Virotek's ophthalmology genetic testing program in the United States for an initial five-year term.10d ago

Similar companies

Lunai Bioworks Inc.LNAI enGene Holdings Inc. WarrantsENGNW IN8bio, Inc.INAB Ainos, Inc.AIMD Brainstorm Cell Therapeutics Inc.BCLI VistaGen Therapeutics, Inc.VTGN Find similar companies →

Latest newsMore news →

KALA BIO added Yenvy Truong, founder of The LSM Group, to its advisory team.3d ago KALA BIO, Inc. signed an exclusive distribution and reseller agreement with Virotek Inc. to distribute Virotek's ophthalmology genetic testing program in the United States for an initial five-year term.10d ago